HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING <130/852 YEARS 130-139/85-891 YEAR 140-149/90-99E & M < 2 MONTHS 160-179/100-109.

Slides:

Advertisements

Similar presentations

CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.

Advertisements

The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

 Cure Pathologic Fear of Hypertension  Create Rational Approach to Drug Choice  Complement Rational Choice with Pearls  Consolidate new information.

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Treatment of Hypertension in Patients over the age of 80 Debra Bynum, MD Associate Professor Division of Geriatric Medicine.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Managing ISOLATED SYSTOLIC HYPERTENION in the Elderly Ass. Prof. Roland KASSAB Head of Division of Cardiology Hotel-Dieu de France, Beirut 12 April 2003.

Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.

Clinical Update on the JNC 7/8 Hypertension Guidelines

Pharmacological Treatment of Hypertension Update 2012.

Hypertension and The Older Patient

Hypertension in the Elderly

Drugs for Hypertension

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,

Nursing Management of Clients with Stressors of Circulatory Function HYPERTENSION NUR133 LECTURE # 10 K. Burger MSEd,MSN, RN, CNE.

ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.

Selection of Antihypertensive Drug. BP ClassificationSystolic BP, mm Hg Diastolic BP, mm Hg Normal

Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid- lowering Treatment to Prevent Heart.

0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.

 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.

PHOTO OF Dr. Thomas 1 Summary of Guidelines JNC VI guidelines focus on: - Absolute risks and benefits used in compiling recommendations - Strong emphasis.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.

1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.

NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf

Blood pressure control in primary health care WORKSHOP

DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.

Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.

Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):

Hypertension: New Trials – Best Treatments Karen Moncher, MD Assistant Professor University of Wisconsin School of Medicine and Public Health.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

UPDATE ON MANAGEMENT OF HYPERTENSION. Classification of BLOOD PRESSURE for adults 18 yrs. Or older BP ClassificationSystolic BP, mm of hgDiastolic BP,

Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.

10/11/ Fasting Glucose Levels & Incident Diabetes Mellitus in Older Non-Diabetic Adults Randomized to Three Different Classes of Antihypertensive.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

HYPERTENSION Background for understanding the Hypertension literature. Jeffrey J. Kaufhold, MD Nephrology.

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).

A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.

Internal Medicine Workshop Series Laos September /October 2009.

Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy.

Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.

Management of Hypertension according to JNC 7

Hypertension JNC VIII Guidelines.

Drugs for Hypertension

Health and Human Services National Heart, Lung, and Blood Institute

The Anglo Scandinavian Cardiac Outcomes Trial

2017 Guideline for High Blood Pressure in Adults

ALLHAT: What Outcomes Would Have Been Expected?

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Health and Human Services National Heart, Lung, and Blood Institute

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Primary Hypertension Max C. Reif, M.D.

The following slides highlight a report by Dr

Pharmacological Treatment of Hypertension Update 2012

Internal Medicine Workshop Series Laos September /October 2009

Presentation transcript:

HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING <130/852 YEARS / YEAR /90-99E & M < 2 MONTHS / E & M < 1 MONTHS >180/110E & M NOW MODIFY BASED ON AGE, CO-MORBIDITY ALMOST LINEAR RISE IN INCIDENCE WITH AGE

HYPERTENSION AWARENESS, DETECTION, TREATMENT AWARENESS - 73% TREATED - 55% CONTROLLED - 29% % - 53% - 27%

HYPERTENSION BENEFITS OF TREATMENT TREATEDUNTREATED 6 YRS 9.8% 5.0% CVS EVENT REDUCTION 30% IN ALL FEMALES 48% IN BLACK MALES >50% IN WHITE MALES

HYPERTENSION CVS RISK STRATIFICATION MAJOR. TOD OR CCD SMOKING HEART DISEASE DIABETES LVH DYSLIPIDEMIA ANGINA, PRIOR MI GENDER PRIOR CABG/CHF FAMILY HISTORY STROKE OR TIA AGE > 60 YEARS RENAL DIS/ PVD

HYPERTENSION RISK STRATIFICATION & RX BLOOD PRESSURE NO RISK GROUP A 1 RISK GROUP B TOD/ CCD/ DM GROUP C HIGH NORMAL ( /85-89) LIFE STYLE CHANGE DRUG THERAPY STAGE I ( /90-99) LIFE STYLE CHANGE UPTO 1 YEAR LIFE STYLE CHANGE UPTO 6 MOS. DRUG THERAPY STAGE II –III (>160/100) DRUG THERAPY

HYPERTENSION NON PHARMACOLOGIC INTERVENTIONS WEIGHT REDUCTION ++++ SODIUM REDUCTION +++ STRESS REDUCTION + CALCIUM, MAGNESIUM, POTASSIUM FISH OIL +/-

HYPERTENSION ANTIHYPERTENSIVE RESPONSE RESPONSE RATE IN AA POPULATION DILTIAZEM - 85% HCTZ - 60% CLONIDINE - 56% PRAZOSIN - 40% ATENOLOL - 35% CAPTOPRIL - 30% PLACEBO - 20%

SYSTOLIC HYPERTENSION > 60 YRS OF AGE. SYSTOLIC BP RISES. DIASTOLIC BP FALLS. WIDER PULSE PRESSURE. DECREASED ARTERIAL COMPLIANCE INDEPENDENT CVS RISK. ISH – 2-4 FOLD RISK OF MI, LVH, CVA

SYSTOLIC HYPERTENSION SYSTOLIC > 160 mm.Hg. DIASTOLIC < 90 mm.Hg. SYSTOLIC BP > 140 mm.Hg. ABNORMAL AT ANY AGE. ASSOCIATED WITH HIGHER RISK OF STROKE, CVS EVENTS

SYSTOLIC HYPERTENSION SLEW OF TRIALS : SHEP (SYSTOLIC HYPERTENSION IN THE ELDERLY) SYS-EUR STONE TRIAL FROM SHANGHAI SYST-CHINA TRIAL TONE TRIAL STOP TRIAL ALLHAT TRIAL ROTTERDAM STUDY FRAMINGHAM STUDY

SYSTOLIC HYPERTENSION GOALS OF THERAPY LOWER SYSTOLIC BP BY 20mmHg. TO 140 mmHg CONSIDER NON-PHARMACOLGIC APPROACH CAUTIOUS REDUCTION IN ELDERLY SCREEN FOR POSTURAL OR PP BP DROP START WITH “HALF” DOSE CONTROVERSY RE: J – CURVE EXCESSIVE LOWERING (<65 mmHg) OF DIASTOLIC BP MAY INCREASE RISKS.

SYSTOLIC HYPERTENSION THIAZIDE DIURETICS BETA BLOCKERS RESERPINE (!) CA ++ CHANNEL BLOCKERS LONG ACTING NITRATES ACE INHIBITORS ARB-S ALPHA BLOCKERS

SYSTOLIC HYPERTENSION ISOLATED SYSTOLIC HYPERTENSION (ISH) GENERALLY INADEQUATELY TREATED BP > 160 mm.Hg. SHOULD BE ACTIVELY TREATED WITH OR W/O DIASTOLIC HTN MORE STRINGENT CRITERION FOR R X IF ADDITIONAL RISK FACTORS COEXIST SMOKING, DIABETES

SYSTOLIC HYPERTENSION SHEP TRAL (SYST. HYP. IN THE ELDERLY. JAMA 1991) MEAN AGE 72 YRS. 57% FEMALE. 14% AA 4736 PTS. MEAN BP 170/77 mm.Hg IN R X GROUP. BP ACHIEVED 143/68 mm.Hg PLACEBO. BP ACHIEVED 155/72 mm.Hg. AIM TO REDUCE BP AT LEAST 20 mm.Hg. TO <160 SYSTOLIC CHLORTHALIDONE, ATENOLOL, RESERPINE RELATIVE RISK CVA 0.64 CVS 0.73 (NORMOKALEMIA REQUIRED) OVERALL MORTALITY PATIENTS R X FOR 5 YRS TO PREVENT A MAJOR EVENT.

SYSTOLIC HYPERTENSION SYS-EUR TRIAL (LANCET 1997) LONG ACTING DIHYDROPYRIDINES NITRENDIPINE, NIFEDIPINE ACCEPTABLE ALTERNATIVE R X FOR ISH BETA BLOCKERS W/O DIURETICS DO NOT REDUCE CORONARY MORTALITY LONG ACTING NITRATES PREFERENTIALLY LOWER SYSTOLIC BP W/O TACHYPHYLAXIS

SYSTOLIC HYPERTENSION TONE TRIAL (TRIAL OF NON-PHARMACOLOGIC INTERVENTION IN THE ELDERLY) 975 PTS YRS. BP <145/<85 mmHg ON ONE R X Na + RESTRICTION MEQ/DAY. TENDENCY TO INCREASE SALT B/O DIMINISHED TASTE DEPENDENCE ON PROCESSED/PACAKAGED FOOD WEIGHT REDUCTION BOTH NONE

SYSTOLIC HYPERTENSION STOP TRIAL (SWEDISH TRIAL IN OLD PATIENTS) 6614 PTS YRS OF AGE SYSTOLIC > 180 DIASTOLIC > 105 mmHg. BETA BLOCKER/DIURETIC (CAD; TACHYCARDIA) ACEI (ENALAPRIL, LISINOPRIL IN LV DYSFX/CRI/DM) Ca++ CHANNEL BLOCKERS (ANGINA, DIASTOLIC DYSFX, PVD -- ISRADIPINE, FELODIPINE) BP 194/98 TO 159/81 mmHg. NO DIFFERENCE IN YR FOLLOW UP.

SYSTOLIC HYPERTENSION ALLHAT TRIAL (ANTIHYPERTENSIVE & LIPID LOWERING R X TO PREVENT HEART ATTACK TRIAL JAMA 1967, ANN INT MED 2002) ALPHA BLOCKERS - CHF RISK MAY HELP IN PROSTATISM

SYSTOLIC HYPERTENSION TREATMENT THERAPY IS BENEFICIAL IN ISH 20 MM.Hg REDUCTION IN BP TO A LEVEL BELOW 160 MM.Hg (SHEP TRIAL) DIURETICS IN LOW DOSE (THIAZIDE/ K-SPARING) ATENOLOL (25-50 MG) OR RESERPINE (!!! 0.5 MG) ADDED IF REQUIRED LONG ACTING DHP Ca++ CHANNEL BLOCKERS SUSTAINED RELEASE NITRATES ALPHA BLOCKERS (SYS-EUR/ STONE TRIAL) SPECIAL BENEFIT IN DIABETES